PHS Issues Treatment Guidelines for Tobacco Dependency

January 10th 2025

Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL

Elinzanetant met all primary and secondary end points when compared with placebo in patients with HR-positive breast cancer in the phase 3 OASIS-4 trial.

Rachel A. Millstein, PhD, MHS;Loren Winters, NP;Amy Comander, MD

January 6th 2025

FDA Grants BBO-8520 Fast Track Designation for KRASG12C-Mutant mNSCLC

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

The decision was supported by efficacy findings from the phase 1 ONKORAS-101 trial, which evaluated the therapy in KRASG12C non–small cell lung cancer.

Determining Suitable Radioligand Therapy Use in Neuroendocrine Tumors

The decision was supported by efficacy findings from the phase 1 ONKORAS-101 trial, which evaluated the therapy in KRASG12C non–small cell lung cancer.

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Natasha Bahri, MD, MS;Daneng Li, MD

December 30th 2024

Nivolumab/Cisplatin/Radiotherapy Improves DFS in Locally Advanced SCCHN

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

FDA Gives Fast Track Designation to VGT-309 for Lung Tumor Visualization

The phase 3 NIVOPOSTOP GORTEC 2018-01 trial shows that nivolumab added to radiotherapy and cisplatin had improved efficacy over SOC treatments in SCCHN.

Efficacy findings from a phase 2 trial demonstrated that abenacianine visualized lung tumor tissue and was well tolerated when used during surgery.

January 8th 2025

Elinzanetant Reduces The Frequency of Hot Flashes in HR+ Breast Cancer

Efficacy findings from a phase 2 trial demonstrated that abenacianine visualized lung tumor tissue and was well tolerated when used during surgery.

Related Content

January 10th 2025

Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL

Elinzanetant met all primary and secondary end points when compared with placebo in patients with HR-positive breast cancer in the phase 3 OASIS-4 trial.

Rachel A. Millstein, PhD, MHS;Loren Winters, NP;Amy Comander, MD

January 6th 2025

FDA Grants BBO-8520 Fast Track Designation for KRASG12C-Mutant mNSCLC

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Determining Suitable Radioligand Therapy Use in Neuroendocrine Tumors

The decision was supported by efficacy findings from the phase 1 ONKORAS-101 trial, which evaluated the therapy in KRASG12C non–small cell lung cancer.

Natasha Bahri, MD, MS;Daneng Li, MD

December 30th 2024

Nivolumab/Cisplatin/Radiotherapy Improves DFS in Locally Advanced SCCHN

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

FDA Gives Fast Track Designation to VGT-309 for Lung Tumor Visualization

The phase 3 NIVOPOSTOP GORTEC 2018-01 trial shows that nivolumab added to radiotherapy and cisplatin had improved efficacy over SOC treatments in SCCHN.

January 8th 2025